Related Experiment Video

Updated: Aug 7, 2026

On-Chip Endothelial Inflammatory Phenotyping
12:43

On-Chip Endothelial Inflammatory Phenotyping

Published on: July 21, 2012

[Inflammatory concepts of atherosclerosis--clinical utility of C-reactive protein measurement]

Magdalena Gibas1, Jolanta Miszczak-Smiałek

  • 1Z Katedry i Zakładu Fizjologii Akademii Medycznej w Poznaniu. magda.gibas@hipkrates.org

Wiadomosci Lekarskie (Warsaw, Poland : 1960)
|July 4, 2006
PubMed

Insights

C-reactive protein (CRP) is a key marker for vascular inflammation in atherosclerosis. Measuring CRP shows promise for predicting coronary events and guiding heart disease treatment.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Biochemistry

Context:

  • Atherosclerosis is increasingly understood through the lens of inflammation.
  • Identifying reliable inflammatory markers is crucial for managing atherosclerotic diseases.

Purpose:

  • To explore the role of C-reactive protein (CRP) as a marker of vascular inflammation in atherosclerosis.
  • To discuss the clinical utility of CRP testing in predicting coronary events and monitoring therapy.

Summary:

  • C-reactive protein (CRP) is highlighted as a significant and independent marker of vascular inflammation.
  • Its measurement is valuable for predicting future coronary events.
  • CRP testing aids in monitoring the effectiveness of coronary heart disease therapies.

Impact:

  • CRP testing offers promising clinical utility in cardiovascular risk assessment.
  • Understanding CRP's role enhances therapeutic strategies for coronary heart disease.
  • This research supports the integration of inflammatory markers into routine cardiovascular care.

More Related Videos

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty10:03

Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty

Published on: January 28, 2020

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests01:27

Atherosclerosis II: Clinical Manifestations and Diagnostic Tests

Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Inflammation01:38

Inflammation

Overview
Atherosclerosis I: Introduction01:30

Atherosclerosis I: Introduction

Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...